Overcoming Multidrug Resistance by Bacterial Efflux Pump Inhibitors in Clinical Escherichia coli Strains
Antibiotics · 09.03.2026 · 15 (3) · 276
DOI: 10.3390/antibiotics15030276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 09.03.2026. Verfasst von Nikoletta Szemerédi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Albert Szent-Györgyi Medical School, University of Szeged, Hungary, University Research Scholarship Programme (EKÖP), Ministry of Culture and Innovation, Na-tional Research, Development and Innovation Fund, University Research Scholarship Programme (EKÖP), Ministry of Culture and Innovation, National Research, Development and Innovation Fund.
Abstract (Originalsprache)
Background/Objectives: Antimicrobial resistance (AMR) is an escalating global threat driven by antibiotic misuse and bacterial adaptation. Efflux pumps are major contributors to multidrug resistance in Escherichia coli, as they expel antibiotics and reduce their intracellular activity. This study examined efflux-mediated resistance in extended-spectrum beta-lactamase (ESBL)-producing E. coli and evaluated the potential of several efflux pump inhibitors (EPIs)—promethazine (PMZ), thioridazine (TZ), carbonyl cyanide m-chlorophenyl hydrazine (CCCP), reserpine (RES), and phenyl-arginine-β-naphthylamide (PAβN)—as therapeutic adjuncts.
Methods
Antibacterial and anti-biofilm activities of EPIs were tested using broth microdilution, real-time fluorimetry, and crystal violet assays, while ceftriaxone–PMZ interactions were assessed by checkerboard analysis.
Results
TZ and CCCP showed strain-specific antibacterial activity, whereas PMZ, RES, and PAβN did not exert any effect. PMZ, TZ, and especially CCCP effectively inhibited efflux pump function, while RES and PAβN were less active. Biofilm inhibition varied between strains, with PMZ and TZ producing moderate reductions. We observed a quite weak synergism between ciprofloxacin, ceftriaxone, and PMZ; however, the result was not significant.
Conclusions
Overall, the results highlight the central role of efflux pumps in ESBL-producing E. coli and indicate that EPIs can reverse resistance (e.g., PMZ) and exhibit potent anti-biofilm activity and show additive interactions with antibiotics. However, further studies are needed to optimize their safety, pharmacokinetics, and antibiotic pairing for potential clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725 Szeged, Hungary.
ORCID-Profile: Nikoletta Szemerédi, Danhui Heo, László Orosz, József Sóki, Gabriella Spengler
Förderung
- Albert Szent-Györgyi Medical School, University of Szeged, Hungary
- University Research Scholarship Programme (EKÖP), Ministry of Culture and Innovation, Na-tional Research, Development and Innovation Fund
- University Research Scholarship Programme (EKÖP), Ministry of Culture and Innovation, National Research, Development and Innovation Fund
Zitieren
APA
Szemerédi, N., Nové, M., Heo, D., Orosz, L., Sóki, J., & Spengler, G. (2026). Overcoming Multidrug Resistance by Bacterial Efflux Pump Inhibitors in Clinical Escherichia coli Strains. Antibiotics, 15(3), 276. https://doi.org/10.3390/antibiotics15030276
Vancouver
Szemerédi N, Nové M, Heo D, Orosz L, Sóki J, Spengler G. Overcoming Multidrug Resistance by Bacterial Efflux Pump Inhibitors in Clinical Escherichia coli Strains. Antibiotics. 2026;15(3):276. doi:10.3390/antibiotics15030276
BibTeX
@article{Szemerdi2026,
author = {Szemerédi, Nikoletta and Nové, Márta and Heo, Danhui and Orosz, László and Sóki, József and Spengler, Gabriella},
title = {Overcoming Multidrug Resistance by Bacterial Efflux Pump Inhibitors in Clinical Escherichia coli Strains},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {3},
pages = {276},
doi = {10.3390/antibiotics15030276}
}
EUVIMED